2021 yil noyabr: The first clinical trial of South Korea’s homegrown next-generation chimeric antigen receptor T (CAR-T) cell therapy, which is designed to circumvent immune checkpoint signals, has recently gotten under way.
Koreya ilg'or fan va texnologiya instituti (KAIST) chorshanba kuni Seuldagi Samsung tibbiyot markazida CAR-T hujayra terapiyasining 1b-bosqich klinik sinovi o'tkazilayotganini e'lon qildi. Sinov koreyalik 10 nafar bemor bilan o'tkazilmoqda, ular relapsli va refrakter diffuz yirik B hujayrali limfoma. Quvurning marketing huquqi universitetdan professor Kim Chan Xyuk asoschisi bo‘lgan Curocell kompaniyasiga o‘tkazildi. Curocell inqilobchining klinik rivojlanish dasturiga mas'uldir immunoterapiya.
In addition, a Phase 2 klinik tadqiqotlar involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for kimerik antigen retseptorlari T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
Siz o'qishni xohlashingiz mumkin: Koreyada CAR T-Cell terapiyasi
Tadqiqot natijalari "Molekulyar terapiya" jurnalining oktyabr sonida onlayn nashr etilgan maqolada keltirilgan.
